Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Phase I-II evaluation of combination cyclophosphamide, 5-fluorouracil, hexamethyl-melamine, and prednisone in advanced breast cancer

Chang, Yuang-Chi, M.D.a; Falkson, Geoffrey, M.D.b; Tormey, Douglass C., M.D. Ph.D.c; Crowley, John, Ph.D.d

American Journal of Clinical Oncology: January 1981 - Volume 4 - Issue 4 - p 377–380

A FOUR-DRUG COMBINATION of intermittent high-dose cyclophosphamide with 5-fluorouracil. hexamethyl-melamine. and prednisone was given to 19 patients with advanced breast canner. Objective response was documented in 7 of 18 evaluable patients. The median duration of response was 99 days. Response was observed in 6/7 patients without visceral disease and 1/11 patients with vise disease. Toxicity was acceptable and no life-threatering toxicity was observed. Three patients have received the four-drug combination for more than 1 year without serious side effects. This regimen may serve as an alternative treatment for patients without visceral metastasis who have failed to respond to other combination chemotherapy regimens.

a Assistant Professor, Departments of Medicine and Oncology, St Mary's Hospital. Rochester. New York.

b Professpr and Head, Department of Cancer Chemotherapy, University of Pretoria, Republic of South Africa. In receipt of a grant from the National Cancer Association of South Africa.

c Association Proferssor, Department of Human Oncology and Medicine. University of Wisconsin Hospital and Clinics Partly supported by O01-CA 20432 from the National Cancer Institute.

d Associate Professor, Departments of Human Oncology and Statistics, University of Wiseonsin Hospital.

© Lippincott-Raven Publishers.